Pathway Genomics Receives CLIA Certificate of Accreditation

Pathway Genomics, a genetic testing laboratory specializing in screening for nutrition and exercise response, inherited disease, prescription drug response and chronic health condition risks, announced that it has received a Certificate of Accreditation from the U.S. Department of Health and Human Services´ Centers for Medicare and Medicaid, under the Clinical Laboratory Improvement Amendments (CLIA) of 1988.

"CLIA accreditation demonstrates Pathway´s commitment to exceptionally high standards of laboratory testing," said David Becker, Ph.D., Pathway´s chief scientific officer. "Reaching this level of accreditation is an important milestone in the company´s growth."

The objective of CLIA regulations is to ensure quality laboratory testing. While there are several levels of CLIA certification, a Certificate of Accreditation requires the laboratory and its staff to perform at the highest levels of quality.

Last month, Pathway´s laboratory was also accredited by the College of American Pathologists (CAP). Both the CLIA and CAP accreditations signify the company´s dedication to excellence, and help the company bring medically actionable genetic information to physicians and their patients.

About Pathway Genomics

Located in San Diego, California, Pathway Genomics owns and operates an on-site genetic testing laboratory that is accredited by the College of American Pathologists (CAP), accredited in accordance with the U.S. Health and Human Services´ Clinical Laboratory Improvement Amendments (CLIA), and licensed by the state of California. Using customized and scientifically validated genetic testing technologies within a controlled and secure environment, Pathway Genomics conducts comprehensive genotyping and targeted sequencing to generate personalized genetic reports. These reports address a variety of genetic issues, including an individual´s carrier status for recessive genetic conditions, food metabolism and exercise response, drug or medication response, and propensity to develop certain diseases, such as heart disease, type 2 diabetes, and cancer. Pathway´s genotyping services are available to patients through their physicians and select health management programs. For more information about Pathway Genomics, visit www.pathway.com.